# US 10,501,806 B2 · Chromosomal assessment to differentiate histiocytic malignancy from lymphoma in dogs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,501,806 B2
- Document ID: US10501806B2
- Status: Granted
- Kind: B2
- Application number: 15/304,388
- Filed: 2015-04-15
- Published: 2017-02-09
- Granted: 2019-12-10
- Earliest claimed: 2014-04-15
- Assignees: North Carolina State University
- Applicants: North Carolina State University; Matthew Breen
- Inventors: Matthew Breen
- Web page: https://patentgrep.com/patent/US10501806B2

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61P 35/00: Antineoplastic agents
- C12Q 2600/124: Animal traits, i.e. production traits, including athletic performance or the like
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates generally to the discovery of an improved method to differentiate histiocytic malignancy from lymphoma or hemangiosarcoma in dogs.

## Claims

### Claim 1

A method for treating a dog with lymphoma, the method comprising:
(a) measuring copy numbers of CFA 2, CFA 16, and CFA 31 in a biological sample from a dog suspected of having lymphoma or a histiocytic malignancy, wherein:
(i) the biological sample comprises neoplastic cells; and
(ii) the copy numbers of CFA 2, CFA 16, and CFA 31 are measured by aberrations at CFA chr2:31,017,808-31,586,959, CFA chr16:31,674,246-32,429,051, and CFA chr31:33,346,317-33,709,291 from CamFam2, respectively;
(b) detecting a normal or elevated copy number at CFA 2, CFA 16, and CFA 31 compared to a normal control in the biological sample;
(c) diagnosing the dog with lymphoma; and
(d) treating the dog with standard of care (SOC) chemotherapy using either single agent or multiagent protocols.

### Claim 2 (depends on 1)

The method of claim 1, wherein the copy numbers are measured by fluorescence in situ hybridization (FISH).

### Claim 3 (depends on 1)

The method of claim 1, wherein the copy numbers are measured by polymerase chain reaction (PCR).

### Claim 4 (depends on 1)

The method of claim 1, wherein the copy numbers are measured by comparative genomic hybridization (CGH).

### Claim 5 (depends on 1)

The method of claim 1, wherein the copy numbers are measured by next generation sequencing.

### Claim 6 (depends on 1)

The method of claim 1, wherein the biological sample is a tissue sample.

### Claim 7 (depends on 1)

The method of claim 1, wherein the sample is a fresh-frozen sample.

### Claim 8 (depends on 1)

The method of claim 1, wherein the sample is a fresh sample.

### Claim 9 (depends on 1)

The method of claim 1, wherein the sample is a formalin-fixed, paraffin-embedded sample.

### Claim 10 (depends on 1)

The method of claim 1, wherein the copy numbers at CFA 2, CFA 16, and CFA 31 are measured with probes of about 15 to about 1×106 nucleotides in length.

### Claim 11 (depends on 10)

The method of claim 10, wherein the copy numbers are measured with probes of about 5,000 to about 800,000 nucleotides in length.

### Claim 12 (depends on 10)

The method of claim 10, wherein the copy numbers are measured with probes of about 100,000 to about 400,000 nucleotides in length.

### Claim 13

A method for selecting and treating a dog suspected of having a canine lymphoma, the method comprising:
(a) providing a dog suspected of having a lymphoma or a histiocytic malignancy;
(b) measuring copy numbers of CFA 2, CFA 16, and CFA 31 in a biological sample from the dog, wherein:
(i) the biological sample comprises cells obtained directly from a suspected neoplastic mass; and
(ii) the copy numbers of CFA 2, CFA 16, and CFA 31 are measured by aberrations at CFA chr2:31,017,808-31,586,959, CFA chr16:31,674,246-32,429,051, and CFA chr31:33,346,317-33,709,291 from CamFam2, respectively;
(b) detecting normal or elevated copy number at CFA 2, CFA 16, and CFA 31 compared to a normal control in the biological sample;
(c) diagnosing the dog with lymphoma; and
(d) treating the dog with standard of care (SOC) chemotherapy using either single agent or multiagent protocols.

### Claim 14 (depends on 13)

The method of claim 13, wherein the copy numbers at CFA 2, CFA 16, and CFA 31 are measured with probes of about 15 to about 1×106 nucleotides in length.

### Claim 15 (depends on 14)

The method of claim 14, wherein the copy numbers are measured with probes of about 5,000 to about 800,000 nucleotides in length.

### Claim 16 (depends on 14)

The method of claim 14, wherein the copy numbers are measured with probes of about 100,000 to about 400,000 nucleotides in length.